Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RevolKa and La Jolla Institute Partner to Create Antigens for Next-Gen Vaccines | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

RevolKa and La Jolla Institute Partner to Create Antigens for Next-Gen Vaccines

Aim to address unmet medical needs in infectious diseases.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

RevolKa Ltd., a venture-backed biotech company with a protein engineering technology platform, and La Jolla Institute for Immunology (LJI) have initiated a research collaboration to create antigens for next-generation vaccines to address unmet medical needs in infectious diseases.
 
RevolKa has a robust directed protein evolution technology integrated with artificial intelligence (AI), called aiProtein, which is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. LJI and RevolKa will synergize LJI’s deep knowledge of immunology and RevolKa’s power of AI-driven protein engineering.
 
Financial terms of this collaboration were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics